What is IVF Genetic Testing and How Does It Work?

Among the many decisions involved in fertility treatment, IVF genetic testing is one that raises some of the most thoughtful and emotionally weighted questions. For patients who are concerned about passing on a hereditary condition, who have experienced repeated pregnancy loss, or who simply want to understand their options more fully, genetic testing can be a meaningful part of the IVF process. This article explains what IVF genetic testing involves, who it may be relevant for, how results are used in treatment planning, and what patients should realistically expect.

The term IVF genetic testing refers to a group of laboratory procedures collectively known as preimplantation genetic testing (PGT). These tests analyze embryos created through IVF before they are transferred to the uterus, with the aim of identifying chromosomal or genetic abnormalities that may affect whether an embryo implants, develops successfully, or results in a child with a heritable condition. Understanding what is preimplantation genetic testing, and how it fits into a broader fertility treatment plan, is an important step for patients who are weighing this option.

What Is IVF Genetic Testing?

IVF genetic testing is the process of examining embryos at the genetic or chromosomal level before they are transferred during an IVF cycle. Rather than waiting to learn about a pregnancy's genetic status through prenatal testing, PGT allows clinicians to assess embryos in the laboratory at a very early stage, typically five to seven days after fertilization when the embryo has developed into a blastocyst.

The information gathered through preimplantation genetic testing in IVF does not predict every possible health outcome for a future child, and it does not guarantee a successful pregnancy. What it offers is a more informed basis for embryo selection, helping clinicians and patients identify which embryos are most likely to result in a healthy implantation and ongoing pregnancy given the specific factors being tested.

There are several distinct types of PGT, each designed to address a different category of genetic concern. These are covered in detail later in this article. PFCLA provides a comprehensive overview of PGT-A, PGT-M, PGT-SR, and related genetic screening services for patients seeking more clinical detail.

Who May Benefit from IVF Genetic Testing?

IVF genetic testing is not a routine recommendation for every patient undergoing IVF. It is typically discussed in the context of specific clinical histories or personal circumstances that increase the relevance of genetic information. Patients for whom PGT may be particularly worth considering include:

• Those with a personal or family history of a heritable genetic condition
• Individuals or couples who have been identified as carriers of a chromosomal rearrangement, such as a translocation
• Patients who have experienced recurrent pregnancy loss, particularly early losses that may be related to chromosomal abnormalities in the embryo
• Those who have had multiple unsuccessful IVF cycles without a clear explanation
• Patients of advanced maternal age, for whom the statistical likelihood of chromosomal aneuploidy in embryos is higher
• Individuals using donor eggs, donor sperm, or building their family through surrogacy, who may want additional information before proceeding with a transfer

One aspect of genetic risk that patients do not always anticipate is carrier status. Many people carry genetic variants associated with serious heritable conditions without experiencing any symptoms themselves. Preconception carrier screening, which is a separate process from PGT, can identify whether one or both partners carry variants for conditions such as cystic fibrosis, spinal muscular atrophy, or fragile X syndrome. When carrier status is confirmed, this can be a strong clinical indication for PGT-M, the form of genetic testing designed to detect specific known mutations in embryos.

For a detailed look at what carrier screening involves and common misunderstandings around it, this article on misconceptions about genetic carrier screening is a helpful companion read.

How IVF Genetic Testing Works: A Step-by-Step Overview

Preimplantation genetic testing is carried out within the standard IVF cycle. The process involves several coordinated stages, each of which builds on the last.

Ovarian Stimulation and Egg Retrieval

The process begins with hormonal stimulation to encourage the development of multiple follicles. Once the follicles have reached an appropriate size, eggs are retrieved in a short outpatient procedure performed under sedation. The goal is to retrieve enough mature eggs to allow for the development of multiple embryos, which improves the probability that some will be suitable for testing and transfer.

Fertilization

Retrieved eggs are fertilized in the laboratory, typically using intracytoplasmic sperm injection (ICSI), in which a single sperm is injected directly into each mature egg. ICSI is commonly used alongside PGT to minimize the risk of additional sperm DNA contaminating the biopsy sample during genetic analysis.

Embryo Development and Monitoring

Fertilized eggs develop over five to seven days in a carefully controlled laboratory environment. Embryologists monitor growth closely, and those that reach the blastocyst stage are considered candidates for biopsy. Not every fertilized egg will reach this stage, which is a normal part of the process.

Embryo Biopsy

At the blastocyst stage, a small number of cells (usually around five) are carefully removed from the trophectoderm, which is the outer layer of the embryo that will later develop into the placenta. The inner cell mass, which forms the fetus itself, is not disturbed. This biopsy is performed by a skilled embryologist and, when carried out by an experienced team, carries a low risk of harm to the embryo.

Cryopreservation

Following biopsy, embryos are cryopreserved (frozen) while the extracted cells are sent to a specialist genetics laboratory for analysis. Freezing embryos at this stage is standard practice and allows time for testing without requiring an immediate transfer.

Genetic Analysis

The biopsied cells are analyzed in a specialist laboratory using advanced genomic platforms. Depending on the type of testing being performed, analysis may examine the number and structure of all chromosomes, screen for a specific known gene mutation, or assess for structural chromosomal rearrangements. Results typically take one to two weeks to return, though this can vary depending on the laboratory and the complexity of testing involved.

Results Review and Embryo Selection

Results are returned to the treating fertility clinic and reviewed with the patient by a specialist. Embryos identified as chromosomally normal or unaffected by the specific condition being tested are prioritized for transfer in a subsequent frozen embryo transfer (FET) cycle. Any embryos with inconclusive results are discussed individually, and the care team provides guidance on how to interpret and act on those findings.

Types of IVF Genetic Testing

There are three primary forms of preimplantation genetic testing in IVF, each serving a distinct clinical purpose:

PGT-A: Aneuploidy Screening

PGT-A (preimplantation genetic testing for aneuploidy) is the most widely used form of IVF genetic testing. It examines embryos for an abnormal number of chromosomes, a condition known as aneuploidy. Chromosomal aneuploidy is one of the most common causes of failed implantation, early miscarriage, and conditions such as Down syndrome (trisomy 21). PGT-A identifies embryos with the expected number of chromosomes (euploid embryos) and flags those with numerical abnormalities. PGT-A can also identify the sex chromosomes of each embryo, providing information about the embryo's genetic sex.

PGT-M: Monogenic Disorder Testing

PGT-M (preimplantation genetic testing for monogenic or single-gene disorders) is used when one or both partners carry a known mutation associated with a specific heritable condition. Examples include BRCA mutations linked to hereditary cancer syndromes, cystic fibrosis, sickle cell disease, Tay-Sachs disease, and Huntington's disease. PGT-M requires advance laboratory preparation specific to the mutation in question, which means this type of testing needs to be planned before the IVF cycle begins.

PGT-SR: Structural Rearrangement Testing

PGT-SR (preimplantation genetic testing for structural rearrangements) is designed for individuals who carry chromosomal rearrangements such as translocations or inversions. These structural variants can result in embryos with unbalanced chromosomal material, increasing the risk of miscarriage or developmental differences. PGT-SR identifies which embryos carry chromosomal arrangements that are balanced or normal.

Note: It is also worth noting that PGT-M and PGT-SR can each be performed in combination with PGT-A, allowing patients to screen for both chromosomal aneuploidy and a specific genetic condition or structural rearrangement within the same IVF cycle. A fertility specialist can advise on whether combination testing is appropriate based on individual circumstances.

Will Genetic Testing Catch Every Possible Disorder?

This is one of the most important questions patients ask, and it deserves a direct and honest answer. IVF genetic testing is a powerful clinical tool, but it is not comprehensive in scope.

PGT-A screens specifically for chromosomal aneuploidy. It does not detect single-gene disorders unless PGT-M is also performed. PGT-M is highly targeted to a known, pre-identified mutation and does not simultaneously screen for all possible genetic variants. Some conditions arise spontaneously (de novo) and cannot be predicted or detected through any form of preconception or preimplantation screening. There is also a small but acknowledged possibility of false positive or false negative results in any laboratory-based test, even those performed under rigorous quality standards.

This is why standard prenatal care, including any recommended prenatal screening or diagnostic testing, remains important even after a successful embryo transfer following PGT. Genetic testing at the preimplantation stage reduces certain categories of risk and informs embryo selection; it does not replace ongoing clinical monitoring during pregnancy.

A balanced discussion of the advantages and trade-offs of genetic screening is available in this overview of the pros and cons of PGS and PGT-A.

Can Genetic Testing Identify Issues with Eggs or Sperm?

IVF genetic testing at the embryo level does not directly test eggs or sperm in isolation. However, the results of PGT can provide meaningful indirect information about gamete quality.

If a significant proportion of embryos from a cycle are found to be aneuploid, this may suggest that egg or sperm quality is contributing to chromosomal abnormalities, though it does not confirm this definitively. In such cases, a fertility specialist would typically review the full clinical picture, including the patient's age, response to stimulation, sperm parameters, and overall cycle outcomes, before drawing conclusions or recommending a change in approach.

Separate sperm DNA fragmentation testing is available and can provide more direct information about sperm quality when this is a concern. Similarly, patients considering the use of donor eggs or donor sperm may wish to understand how genetic testing integrates with that pathway, and a specialist can help clarify what testing is and is not relevant in those scenarios.

What If All Embryos Have Genetic Issues?

Learning that all tested embryos have been identified as abnormal or affected is one of the most distressing outcomes a patient can receive, and it is important to approach this situation with both honesty and care.

When this occurs, a fertility specialist would typically discuss the available paths forward. These may include undergoing another stimulation cycle to create and test additional embryos, exploring the use of donor eggs or donor sperm if gamete quality is considered a contributing factor, or in some cases, reconsidering certain embryos that may have been classified as mosaic (containing a mix of normal and abnormal cells) in consultation with a specialist.

In the context of surrogacy, patients sometimes ask whether a gestational surrogate has any role in, or authority over, the genetic testing process. The clinical pathway for embryo testing is determined entirely by the medical team and the intended parents before a surrogate is involved. A gestational surrogate carries an embryo but has no decision-making role over how that embryo was created, selected, or tested. These matters are also addressed within the legal agreements that govern surrogacy arrangements.

For patients facing this situation, the most important step is a thorough conversation with a reproductive specialist who can review the full picture, including cycle history, embryo quality data, and individual health factors, before recommending a next step.

How PGT Results Influence Embryo Transfer Decisions

One of the more significant but underappreciated ways IVF genetic testing shapes treatment is through its influence on embryo transfer strategy. When an embryo has been confirmed as euploid through PGT-A, clinicians have more information to support the decision to proceed with a single embryo transfer (SET).

Elective single embryo transfer reduces the risk of multiple pregnancy, which carries its own medical complexities for both the patient carrying the pregnancy and any resulting children. Where genetic testing confirms embryo status, it can give clinicians greater confidence in recommending SET, potentially making the overall treatment pathway both safer and more straightforward.

Conversely, when embryos have not been tested or when results are inconclusive, transfer decisions may involve a different balance of considerations. The interaction between genetic testing results and transfer strategy is an area where individualized clinical guidance is particularly valuable.

How Long Does IVF Genetic Testing Add to the Process?

Incorporating PGT into an IVF cycle does extend the overall timeline, and for patients who are already managing the emotional weight of fertility treatment, this is a genuinely significant consideration.

The biopsy itself takes place during the same cycle as egg retrieval and embryo development. Following biopsy and embryo freezing, laboratory analysis typically takes one to two weeks. The embryo transfer then takes place in a separate, subsequent cycle. This means that, compared to a fresh embryo transfer, adding PGT introduces at least one additional cycle and several weeks of waiting time.

For many patients, the wait for genetic results is one of the most emotionally demanding parts of the process. Anxiety about what results will show, uncertainty about how to interpret findings, and the difficulty of making significant decisions based on clinical data are all real and understandable experiences. Fertility clinics with integrated psychological support, or referrals to counselors who specialize in reproductive health, can provide meaningful help during this period.

The Role of Genetic Counselling in IVF

For patients with a known genetic condition, a family history of heritable disease, or confirmed carrier status, a consultation with a genetic counselor is often recommended before or alongside IVF treatment. Genetic counselors are specialists trained to help individuals and couples understand the nature of genetic conditions, assess personal risk, and navigate the implications of testing decisions.

A genetic counselor can explain what a specific mutation or chromosomal variant means in practical terms, help patients understand what PGT-M or PGT-SR can and cannot detect in their specific situation, and provide a space to discuss the emotional and ethical dimensions of these decisions without pressure. They work alongside the fertility care team rather than in place of it, and their involvement can help ensure that patients feel genuinely informed before committing to a testing approach.

Even for patients without a confirmed genetic diagnosis, a genetic counselor can help clarify what carrier screening results mean and how they should influence treatment planning. This is an often overlooked resource that can make the overall experience of navigating IVF genetic testing feel more manageable.

Insurance Coverage and the Cost of IVF Genetic Testing

Cost is a practical and legitimate concern for many patients considering genetic testing as part of IVF. PGT adds to the overall expense of treatment, and the extent of insurance coverage varies significantly depending on the provider, the plan, and the clinical indication.

Some insurance plans cover genetic testing when there is a documented medical necessity, such as a confirmed carrier status, a history of recurrent pregnancy loss, or a diagnosis that makes chromosomal screening clinically appropriate. In other cases, PGT is treated as an elective add-on and covered partially or not at all.

For a more detailed breakdown of what patients typically encounter when budgeting for genetic testing as part of IVF, this overview of PGT-A testing costs outlines the key cost components and factors that influence pricing. Fertility clinics often have financial counselors available to help patients understand their coverage and explore financing options where needed.

Understanding Your Options with PFCLA

IVF genetic testing is a nuanced area of reproductive medicine, and the right approach depends on a patient's individual medical history, genetic background, treatment goals, and personal values. There is no single answer that applies to every situation, and the decisions involved deserve careful, individualized clinical guidance.

Pacific Fertility Center Los Angeles brings extensive experience in IVF and preimplantation genetic testing to patients across a wide range of circumstances. Whether patients are exploring PGT for the first time, navigating unexpected results, or trying to understand how genetic testing might fit into their broader treatment plan, the PFCLA team is available to provide clear, evidence-based guidance.

If you have questions about IVF genetic testing or would like to discuss your options with a specialist, PFCLA welcomes you to reach out and schedule a consultation. Personalized care and clinical clarity are available at every stage of the process.